Synaptogenix CEO Dr. Tuchman’s Tenure Extended Through 2024
Company Announcements

Synaptogenix CEO Dr. Tuchman’s Tenure Extended Through 2024

An announcement from Synaptogenix (SNPX) is now available.

Synaptogenix, Inc. has extended the term of Dr. Alan J. Tuchman, their CEO, through an amendment to his offer letter, now ensuring his leadership until at least December 7, 2024, with the possibility of monthly renewals. This move solidifies Dr. Tuchman’s role at the helm of the company, indicating a sustained direction for investors and stakeholders to anticipate in the company’s strategic journey ahead.

Learn more about SNPX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlySynaptogenix files to sell 11.93M shares of common stock for holders
TheFlySynaptogenix collaborating with LSU Health New Orleans in spinal cord injury
TheFlySynaptogenix upgraded to Buy from Hold at Maxim
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App